EUVIMEDEUVIMED entdecken
Open Access

Type 2 inflammation reduces SARS-CoV-2 replication in the airway epithelium in allergic asthma through functional alteration of ciliated epithelial cells

Naresh Doni Jayavelu, Matthew C Altman, Basilin Benson, Matthew J Dufort, Elizabeth R Vanderwall, Lucille M Rich, Maria P White, Patrice M Becker, Alkis Togias, Daniel J Jackson, Jason S Debley

Journal of Allergy and Clinical Immunology · 2023

DOI: 10.1016/j.jaci.2023.03.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023. Verfasst von Naresh Doni Jayavelu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Systems Immunology Division, Benaroya Research Institute at Virginia Mason, Seattle, Wash. Hauptthemen laut MEDLINE: COVID-19, Asthma. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite well-known susceptibilities to other respiratory viral infections, individuals with allergic asthma have shown reduced susceptibility to severe coronavirus disease 2019 (COVID-19). OBJECTIVE: We sought to identify mechanisms whereby type 2 inflammation in the airway protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using bronchial airway epithelial cells (AECs) from aeroallergen-sensitized children with asthma and healthy nonsensitized children. METHODS: We measured SARS-CoV-2 replication and ACE2 protein and performed bulk and single-cell RNA sequencing of ex vivo infected AEC samples with SARS-CoV-2 infection and with or without IL-13 treatment. RESULTS: We observed that viral replication was lower in AECs from children with allergic asthma than those from in healthy nonsensitized children and that IL-13 treatment reduced viral replication only in children with allergic asthma and not in healthy children. Lower viral transcript levels were associated with a downregulation of functional pathways of the ciliated epithelium related to differentiation as well as cilia and axoneme production and function, rather than lower ACE2 expression or increases in goblet cells or mucus secretion pathways. Moreover, single-cell RNA sequencing identified specific subsets of relatively undifferentiated ciliated epithelium (which are common in allergic asthma and highly responsive to IL-13) that directly accounted for impaired viral replication. CONCLUSION: Our results identify a novel mechanism of innate protection against SARS-CoV-2 in allergic asthma that provides important molecular and clinical insights during the ongoing COVID-19 pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AsthmaChildHumansSARS-CoV-2Interleukin-13PandemicsInflammationEpithelial CellsEpithelium

Stichwörter der Autor:innen

COVID-19IL-13SARS-CoV-2airway epithelial cellsasthmachildrenepithelium

Substanzen

Interleukin-13

Autor:innen und Institutionen

  • Systems Immunology Division, Benaroya Research Institute at Virginia Mason, Seattle, Wash.
  • Systems Immunology Division, Benaroya Research Institute at Virginia Mason, Seattle, Wash; Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, Wash. Electronic address: mal…
  • Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, Wash.
  • Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Wash.
  • National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, Md.
  • Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wis.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Bill and Melinda Gates Foundation
  • National Institutes of Health
  • GlaxoSmithKline
  • Vifor Pharma
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Doni Jayavelu, N., Altman, M. C., Benson, B., Dufort, M. J., Vanderwall, E. R., Rich, L. M., White, M. P., Becker, P. M., Togias, A., Jackson, D. J., & Debley, J. S. (2023). Type 2 inflammation reduces SARS-CoV-2 replication in the airway epithelium in allergic asthma through functional alteration of ciliated epithelial cells. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.03.021

Vancouver

Doni Jayavelu N, Altman MC, Benson B, Dufort MJ, Vanderwall ER, Rich LM, et al. Type 2 inflammation reduces SARS-CoV-2 replication in the airway epithelium in allergic asthma through functional alteration of ciliated epithelial cells. Journal of Allergy and Clinical Immunology. 2023. doi:10.1016/j.jaci.2023.03.021

BibTeX
@article{DoniJayavelu2023,
  author = {Doni Jayavelu, Naresh and Altman, Matthew C and Benson, Basilin and Dufort, Matthew J and Vanderwall, Elizabeth R and Rich, Lucille M and White, Maria P and Becker, Patrice M and Togias, Alkis and Jackson, Daniel J and Debley, Jason S},
  title = {Type 2 inflammation reduces SARS-CoV-2 replication in the airway epithelium in allergic asthma through functional alteration of ciliated epithelial cells},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  doi = {10.1016/j.jaci.2023.03.021}
}
Kostenlos starten →